Nat. Med. | 综述：ADC的“精准”为什么常败给毒性？
Ranking
No observed public metrics; popularity remains neutral/archived.
Merged summary
TL;DR - A Nature Medicine review (published Aug 3) argues that antibody-drug conjugates (ADCs) fail clinically not from lack of "targeting" but from a coupled multivariable system — target expression, internalization, tumor penetration, payload release, bystander effect and host metabolism — where toxicity, not potency, is the gating variable. It matters because it reframes next-gen ADC development as an integrated design + patient-selection + dosing problem rather than a component-swap exercise.
- Single-module upgrades (stronger payload, higher DAR, cleavable linkers) rarely deliver meaningful clinical benefit: higher potency also raises normal-tissue exposure, higher DAR can alter PK/biodistribution, and cleavable linkers increase free payload in circulation and the tumor microenvironment.
- IHC positivity is insufficient for patient selection; the review calls for multidimensional companion diagnostics integrating target surface density and spatial uniformity, internalization efficiency, payload sensitivity, DNA-damage-repair status, resistance transporters, and immune microenvironment — effectively a "delivery capability + drug sensitivity" joint assessment.
- Toxicity is treated as a primary variable: T-DXd-associated interstitial lung disease is attributed not simply to HER2 lung expression but to distribution, payload release, non-specific antibody uptake, linker stability and local immune response — so the goal shifts from maximizing MTD to sustainable dose intensity and a stable therapeutic window across multiple cycles.
- "Next generation" is framed as a combination strategy (dual-payload, bispecific ADCs, novel linkers, site-specific conjugation) that still requires in-patient validation; the proposed direction is building libraries of antibody/linker/payload/DAR combinations matched to individual tumor biology.
Sources (1)
Nat. Med. | 综述：ADC的“精准”为什么常败给毒性？
TL;DR - A Nature Medicine review (published Aug 3) argues that antibody-drug conjugates (ADCs) fail clinically not from lack of "targeting" but from a coupled multivariable system — target expression, internalization, tumor penetration, payload release, bystander effect and host metabolism — where toxicity, not potency, is the gating variable. It matters because it reframes next-gen ADC development as an integrated design + patient-selection + dosing problem rather than a component-swap exercise.
- Single-module upgrades (stronger payload, higher DAR, cleavable linkers) rarely deliver meaningful clinical benefit: higher potency also raises normal-tissue exposure, higher DAR can alter PK/biodistribution, and cleavable linkers increase free payload in circulation and the tumor microenvironment.
- IHC positivity is insufficient for patient selection; the review calls for multidimensional companion diagnostics integrating target surface density and spatial uniformity, internalization efficiency, payload sensitivity, DNA-damage-repair status, resistance transporters, and immune microenvironment — effectively a "delivery capability + drug sensitivity" joint assessment.
- Toxicity is treated as a primary variable: T-DXd-associated interstitial lung disease is attributed not simply to HER2 lung expression but to distribution, payload release, non-specific antibody uptake, linker stability and local immune response — so the goal shifts from maximizing MTD to sustainable dose intensity and a stable therapeutic window across multiple cycles.
- "Next generation" is framed as a combination strategy (dual-payload, bispecific ADCs, novel linkers, site-specific conjugation) that still requires in-patient validation; the proposed direction is building libraries of antibody/linker/payload/DAR combinations matched to individual tumor biology.